The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
A bone marrow toxicity model for 223 Ra alpha-emitter radiopharmaceutical therapy
Open accessAbstract
Ra-223, an α-particle emitting bone-seeking radionuclide, has recently been used in clinical trials for osseous metastases of prostate cancer. We investigated the relationship between absorbed fraction-based red marrow dosimetry and cell level-dosimetry using a model that accounts for the expected localization of this agent relative to marrow cavity architecture. We show that cell level-based dosimetry is essential to understanding potential marrow toxicity. The GEANT4 software package was used to create simple spheres representing marrow cavities. Ra-223 was positioned on the trabecular bone surface or in the endosteal layer and simulated for decay, along with the descendants. The interior of the sphere was divided into cell-size voxels and the energy was collected in each voxel and interpreted as dose cell histograms. The average absorbed dose values and absorbed fractions were also calculated in order to compare those results with previously published values. The absorbed dose was predominantly deposited near the trabecular surface. The dose cell histogram results were used to plot the percentage of cells that received a potentially toxic absorbed dose (2 or 4 Gy) as a function of the average absorbed dose over the marrow cavity. The results show (1) a heterogeneous distribution of cellular absorbed dose, strongly dependent on the position of the cell within the marrow cavity; and (2) that increasing the average marrow cavity absorbed dose, or equivalently, increasing the administered activity resulted in only a small increase in potential marrow toxicity (i.e. the number of cells receiving more than 4 or 2 Gy), for a range of average marrow cavity absorbed doses from 1 to 20 Gy. The results from the trabecular model differ markedly from a standard absorbed fraction method while presenting comparable average dose values. These suggest that increasing the amount of radioactivity may not substantially increase the risk of toxicity, a result unavailable to the absorbed fraction method of dose calculation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Average marrow absorbed dose from antibody, peptide, or small molecule -based a RPT is likely to predict hematologic toxicity whereas bone targeting agents such as 223 RaCl2 will overestimate the potential biologic impact of a calculated average marrow absorbed dose ( 45 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [45]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Average marrow absorbed dose from antibody, peptide, or small molecule -based a RPT is likely to predict hematologic toxicity whereas bone targeting agents such as 223 RaCl2 will overestimate the potential biologic impact of a calculated average marrow absorbed dose ( 45 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Basic anatomical and physiological data for use in radiological protection: reference values
Valentin, J. (2002) · Annals of the ICRP · doi:10.1016/s0146-6453(03)00002-2 · Cited by 2,024
Stabin, M. G., Sparks, R. B., & Crowe, E. A. (2005) · PubMed · Cited by 1,340
Bolch, W. E., Eckerman, K. F., Sgouros, G., & Thomas, S. R. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.056036 · Cited by 913
Self-citationErlandsson, K., Buvat, I., Pretorius, P. H., Thomas, B. A., & Hutton, B. F. (2012) · Physics in Medicine and Biology · doi:10.1088/0031-9155/57/21/r119 · Cited by 731
MIRD primer for absorbed dose calculations
LOEVINGER, R., Budinger, T. F., & Watson, E. E. (1988) · Medical Entomology and Zoology · Cited by 552
Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552
Self-citationNilsson, S. F., Franzén, L., Parker, C. C., Tyrrell, C., Blom, R., Tennvall, J., Lennernäs, B., Petersson, U., Johannessen, D. C., Sokal, M., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70147-x · Cited by 493
Radioimmunotherapy with alpha-emitting nuclides
McDevitt, M. R., Sgouros, G., Finn, R. D., Humm, J. L., Jurcic, J. G., Larson, S. M., & Scheinberg, D. A. (1998) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050306 · Cited by 403
Self-citationBruland, Ø. S., Nilsson, S. F., Fisher, D. R., & Larsen, R. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0841 · Cited by 356
MIRD Primer for Absorbed Dose Calculations
Malamud, H. (1989) · Clinical Nuclear Medicine · doi:10.1097/00003072-198909000-00027 · Cited by 328
Research works printed but not linked: 10
- Akabani G, 2003, J. Nucl. Med., 44, 792
- Henriksen G, 2002, Cancer Res., 62, 3120
- Henriksen G, 2003, J. Nucl. Med., 44, 252
- 2003, ICRP Publication, 89
- Lewington V J, 2010, ASCO Genitourinary Cancers Symp.
- Liepe K, 2009, Curr. Opin. Investig. Drugs, 10, 1346
- Sgouros G, 1993, J. Nucl. Med., 34, 689
- Shah A P, 2003, J. Nucl. Med., 44, 774
- Stabin M G, 2005, J. Nucl. Med., 46, 1023
- Watchman C J, 2005, J. Nucl. Med., 46, 1171
Cited by
Sorted by citations
Radiopharmaceutical therapy in cancer: clinical advances and challenges
Sgouros, G., Bodei, L., McDevitt, M. R., & Nedrow, J. R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0073-9 · Cited by 1,032
Self-citationA Critical Review of Alpha Radionuclide Therapy—How to Deal with Recoiling Daughters?
de Kruijff, R. M., Wolterbeek, H. T., & Denkova, A. G. (2015) · Pharmaceuticals · doi:10.3390/ph8020321 · Cited by 254
Carrasquillo, J. A., O’Donoghue, J. A., Pandit-Taskar, N. D., Humm, J. L., Rathkopf, D. E., Slovin, S. F., Williamson, M. J., Lacuna, K. P., Aksnes, A.-K., Larson, S. M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2427-6 · Cited by 184
Self-citationDosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride
Pacilio, M., Ventroni, G., Vincentis, G. D., Cassano, B., Pellegrini, R., Castro, E. D., Frantellizzi, V., Follacchio, G. A., Garkavaya, T., Lorenzon, L., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3150-2 · Cited by 146
Dosimetry of 223Ra-chloride: dose to normal organs and tissues
Laßmann, M., & Noßke, D. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2265-y · Cited by 125
Metadata
- Authors
- Hobbs, R. F., Song, H., Watchman, C. J., Bolch, W. E., Aksnes, A.-K., Ramdahl, T., Flux, G. D., & Sgouros, G.
- Affiliations
- Johns Hopkins University (US)
- University of Arizona (US)
- University of Florida (US)
- Royal Marsden NHS Foundation Trust (GB)
- Corresponding author
- Hobbs, Robert F
- Watchman, Christopher J
- Bolch, Wesley E
- Aksnes, Anne-Kirsti
- Ramdahl, Thomas
- Flux, Glenn D
- Sgouros, George
- Venue
- Physics in Medicine and Biology
- Publisher
- IOP Publishing
- Published
- 2012-05-01
- Volume
- 57
- Issue
- 10
- Pages
- 3207-3222
- ISSN
- 0031-9155 (ISSN-L)
- 1361-6560
- PMC
- PMC3442928
- OpenAlex
- W2109768758
- Cited by
- 122
- References
- 43
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 3 · 2023: 4 · 2022: 13 · 2021: 11 · 2020: 14 · 2019: 8 · 2018: 8 · 2017: 7 · 2016: 13 · 2015: 13 · 2014: 6 · 2013: 7 · 2012: 3
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Physics in Medicine and Biology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000064)
- National Cancer Institute (R01CA157542, R01CA116477)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Physical Sciences › Physics and Astronomy › Radiation › Radioactivity and Radon Measurements
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
- Keywords
- radium-223, alpha-emitting radiopharmaceuticals, myelosuppression, fraction absorbed, trabecular bone, bone-seeking radionuclides, prostate cancer bone metastasis, absorbed dose distribution, Geant4 simulation
- MeSH terms
- Alpha Particles, Bone Marrow, Models, Biological, Radiation Dosage, Radium, Radiopharmaceuticals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
